Aromatase Inhibitors

Mei Ka Fong; Preeti Patel

Aromatase Inhibitors

Author: Mei Ka Fong Editor: Preeti Patel Updated: 7/5/2026 11:12:19 PM

Indications

Aromatase inhibitors are indicated in the treatment of hormone receptor–positive breast cancer in postmenopausal women in various settings. Studies have shown that they are effective when used as adjuvant therapy to chemotherapy and surgery in metastatic estrogen-dependent breast cancer. The use of aromatase inhibitors in preventative and adjuvant therapies for other conditions is currently under investigation.[1][2] Fadrozole and formestane are second-generation aromatase inhibitors that exhibit lower specificity for aromatase and are associated with a higher risk of adverse effects, such as nausea, vomiting, and rashes, compared with third-generation aromatase inhibitors.[3] Currently, 3 third-generation aromatase inhibitors are available.[4][3]

FDA-Approved Indications

Anastrozole:

First-line treatment of postmenopausal women with hormone receptor–positive or hormone receptor–unknown locally advanced or metastatic breast cancer: 1 mg orally once daily until tumor progression or unacceptable toxicity.[5]
Adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer: 1 mg orally once daily. (Adjuvant endocrine therapy for hormone receptor–positive early breast cancer is typically administered for 5 to 10 years, with extended aromatase inhibitor therapy considered in selected patients based on recurrence risk, nodal status, and treatment tolerability.)
Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor–negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole.

Exemestane:

Adjuvant treatment of postmenopausal women with estrogen receptor–positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to exemestane for completion of a total of 5 consecutive years of adjuvant endocrine therapy.
Treatment of postmenopausal women with advanced breast cancer whose disease has progressed following tamoxifen therapy.[6]

Letrozole:

Adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer.
Extended adjuvant treatment of postmenopausal women with early breast cancer who have completed prior standard adjuvant tamoxifen therapy.
First-line treatment of postmenopausal women with hormone receptor–positive or hormone receptor–unknown advanced breast cancer.
Second-line treatment of postmenopausal women with advanced breast cancer following antiestrogen therapy.[7]

Off-Label Uses

Treatment of benign conditions such as cyclic breast pain and recurrent fibrocystic disease.[8]
Treatment of symptomatic myomas and endometriosis as an alternative to surgical intervention.[9]
Ovulation induction in the treatment of infertility.[10]
Treatment of male breast cancer.[11]
Treatment of prostate cancer.[8]
Treatment of late-onset hypogonadism or partial androgen deficiency, obesity-related hypogonadotropic hypogonadism, and male subfertility.[12]
Treatment of rare pediatric conditions associated with sex steroid excess.[13]
Treatment of boys with short stature and constitutional delay of puberty.[13]
Prevention of the initial estrogen flare effect of gonadotropin-releasing hormone agonist treatment.[9]
Treatment of recurrent Müllerian cancer.[14]
Adjuvant treatment of premenopausal women with hormone receptor–positive high-risk breast cancer, in conjunction with ovarian suppression.[15][16]
Prevention of breast cancer in postmenopausal women older than 35 who are at a high risk of breast cancer occurrence.[17]

Mechanism of Action

Register For Free And Read The Full Article

Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.

Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities

Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Aromatase inhibitors inhibit the activity of the enzyme aromatase. Two types of aromatase inhibitors exist: steroidal and nonsteroidal. Steroidal aromatase inhibitors form a covalent bond with the aromatase enzyme, which permanently inactivates the enzyme. In contrast, nonsteroidal aromatase inhibitors form noncovalent bonds and have the potential to be displaced by other molecules.[18] Aromatase, also known as estrogen synthetase, is a member of the cytochrome P450 superfamily of monooxygenases and catalyzes the demethylation of 19-carbon androgens, producing phenolic 18-carbon estrogens.[19] In postmenopausal women, the conversion of androgens to estrogens via this pathway in the adrenal glands, skin, muscle, and adipose tissue is the primary source of estrogen. Aromatase inhibitors block this pathway and consequently suppress estrogen levels in postmenopausal women. Breast cancer cells also demonstrate aromatase activity, which may serve as a local source of estrogen for tumor growth. The inhibition or inactivation of aromatase suppresses serum estrogen levels, which decreases estrogen-mediated cancer cell proliferation in hormone receptor–positive breast cancer.[20]

In premenopausal women, aromatase inhibitors induce an increase in gonadotropin secretion secondary to the reduced negative feedback of estrogen to the pituitary, resulting in ovarian stimulation. Clinicians may use aromatase inhibitors to induce ovulation in the treatment of infertility.[21][20] Aromatase activity increases in endometriosis, with extrauterine endometrial tissue acting as a source of estrogens. Estrogen stimulates the synthesis of PGE2, which further increases aromatase activity in the endometrium. This vicious cycle leads to the growth of ectopic endometrial tissue, which is blocked by aromatase inhibitors by inhibiting the synthesis of estrogen in extrauterine endometrial tissue.[22][23]

In men, excess estrogen is associated with premature closure of the epiphyses. Aromatase inhibitors decrease estrogen by inhibiting the conversion of testosterone to estrogen and have therefore been used in patients with short stature or constitutional delay of puberty. Lowering estrogen levels is associated with an increase in luteinizing hormone, follicle-stimulating hormone, and testosterone. Therefore, aromatase inhibitors have also been used in late-onset hypogonadism or partial androgen deficiency. In men with obesity, increased conversion of androgens to estrogen occurs in adipose tissue, leading to elevated estrogen levels. Aromatase inhibitors also decrease this conversion, causing decreased estrogen and increased testosterone and follicle-stimulating hormone in men with obesity-related hypogonadotropic hypogonadism and male subfertility.[24]

Administration

Anastrozole is a selective nonsteroidal aromatase inhibitor available as a 1-mg tablet, taken orally once daily, with or without food.

First-line treatment of postmenopausal women with hormone receptor–positive or hormone receptor–unknown locally advanced or metastatic breast cancer: 1 mg orally once daily until tumor progression or unacceptable toxicity.
Adjuvant treatment of postmenopausal women with hormone receptor–positive early breast cancer: 1 mg orally once daily. (Adjuvant endocrine therapy for hormone receptor–positive early breast cancer is typically administered for 5 to 10 years, with extended aromatase inhibitor therapy considered in selected patients based on recurrence risk, nodal status, and treatment tolerability.)
No dose adjustment is necessary for older patients or those with renal or liver impairment.

Letrozole is also a selective nonsteroidal aromatase inhibitor available as 2.5-mg tablets.

For postmenopausal breast cancer, the recommended dosage is 2.5 mg orally once daily, with or without food.
As an agent to induce ovulation, the recommended dosage is 2.5 to 5 mg daily for 5 days starting on day 3 of the menstrual cycle.
Renal adjustment is unnecessary if creatinine clearance is above 10 mL/min. Limited data are available on the safety of letrozole in patients with a creatinine clearance of less than 10 mL/min.
In patients with Child-Pugh class C cirrhosis, the dosing interval should be extended to every 48 hours. No dosage recommendations are available for noncirrhotic patients with liver dysfunction. However, since letrozole is extensively metabolized by the liver, caution is warranted in this patient population.

Exemestane is a selective, irreversible steroidal aromatase inhibitor available as 25-mg tablets.

Adjuvant treatment of postmenopausal women with estrogen receptor–positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to exemestane for completion of a total of 5 consecutive years of adjuvant endocrine therapy: 25 mg orally once daily after a meal.
Treatment of postmenopausal women with advanced breast cancer whose disease has progressed following tamoxifen therapy: 25 mg orally once daily after a meal until disease progression.
In the adjuvant setting for premenopausal women with high-risk breast cancer in combination with ovarian suppression, exemestane should be started 6 to 8 weeks after initiating ovarian suppression.[15]
No renal or hepatic dose adjustments are recommended. For the adjuvant treatment of postmenopausal breast cancer following 2 to 3 years of tamoxifen, the recommended dosage of exemestane is 25 mg orally once daily to complete a total of 5 years of endocrine therapy.

The American Society of Clinical Oncology (ASCO) recommends the use of aromatase inhibitors as a component of adjuvant hormonal therapy after surgery for 10 years in postmenopausal patients with early-stage, node-positive, and hormone receptor–positive breast cancer.[25]

Adverse Effects

Various adverse reactions can occur with aromatase inhibitors. Common adverse reactions associated with aromatase inhibitor therapy include hot flashes, asthenia, joint disorders such as arthritis or arthralgia, osteoporosis, fractures, bone pain, back pain, vaginal dryness, dyspareunia, sexual dysfunction, uterine atrophy, hypertension, hyperlipidemia, hypercholesterolemia, thromboembolic events, cardiac and cerebrovascular events, insomnia, and nausea.[20][26][27][28][29]

Rare adverse reactions are as follows:

Skin manifestations may include rash, pruritus, ulcers, and blistering reactions, although severe blistering reactions are rare.
Allergic reactions, such as swelling of the face, lips, tongue, and, occasionally, the throat, can cause difficulty swallowing or breathing.
Liver function abnormality with or without jaundice due to inflammation of the liver.
Bone loss due to estrogen deficiency with long-term use.

Bone loss from aromatase inhibitors caused by the lowering of endogenous estrogens accelerates bone loss and contributes to the increased risk of fractures. No difference in the rate of bone loss has been observed among aromatase inhibitors. However, patients who require ovarian suppression and/or therapies that inhibit endogenous estrogen production, such as aromatase inhibitors, have accelerated bone loss compared to natural menopause.[30] Loss of bone mineral density may be observed within the first 6 months after initiating aromatase inhibitor therapy.[31]

The development of arthralgia, known as aromatase inhibitor–associated arthralgia syndrome, is the most common reason for discontinuation of aromatase inhibitor therapy. Estrogen deficiency leads to decreased bone mineral density, which contributes to joint pain. Estrogen is also linked to the regulation of cytokine activity and the modulation of pain perception in the nervous system.[32] Patients typically present with joint pain and mild swelling in the absence of systemic diseases or other causes. No established therapies have been proven to consistently prevent the development of aromatase inhibitor–associated arthralgia syndrome. However, several studies evaluating pharmacologic and nonpharmacologic interventions have shown potential benefit.[33][34][35][36] The mitigation of aromatase inhibitor–associated arthralgia syndrome continues to be an area of study.[37][38] Data suggest that the combination of an aromatase inhibitor and CDK4/6 inhibitor for adjuvant breast cancer treatment has a lower rate of aromatase inhibitor–associated arthralgia syndrome.[39]

Patients experiencing aromatase inhibitor–associated adverse effects may benefit from switching to an alternative aromatase inhibitor. In a large open-label trial evaluating strategies to reduce early discontinuation of aromatase inhibitor therapy due to adverse effects, approximately 30% of patients with intolerable adverse effects experienced resolution of symptoms after switching to a different aromatase inhibitor.[40]

Contraindications

Two major contraindications to aromatase inhibitors include hypersensitivity and pregnancy.

Hypersensitivity: Aromatase inhibitors are contraindicated in patients with hypersensitivity reactions to these agents. Hypersensitivity reactions may present as anaphylaxis, angioedema, and urticaria.
Pregnancy: Aromatase inhibitors can harm the fetus or cause pregnancy loss in pregnant patients.[41]

Monitoring

All patients on aromatase inhibitors should undergo initial routine laboratory testing, including a complete blood count, serum calcium, vitamin D levels, lipid profile, and liver function tests.[42][43] A baseline bone mineral density assessment with dual-energy x-ray absorptiometry should also be performed before initiating the treatment.[20][44]

Toxicity

Clinical trials have shown that aromatase inhibitors are well tolerated, even at high doses.[44] No dose has been established as life-threatening, and no specific antidote exists for overdose. Standard supportive care, including frequent vital sign monitoring and management of symptoms, is recommended. Patients should be monitored for adverse effects, and treatment should be directed toward maintaining adequate airway, breathing, circulation, and other supportive measures as clinically indicated.

Enhancing Healthcare Team Outcomes

Interprofessional communication among healthcare teams is essential, particularly in the treatment of patients with cancer. Every professional has a vital role to play. Oncologists should select treatment regimens based on current guidelines and individual patient factors. Clinicians should be aware that aromatase inhibitors are typically indicated for postmenopausal patients with hormone receptor–positive breast cancer and may require ovarian function suppression when used in selected premenopausal patients. Oncologists also play an important role in improving adherence to aromatase inhibitors.[45]

Clinicians and nurses should monitor patients for adverse effects of long-term aromatase inhibitor therapy, including osteoporosis, fractures, arthralgia, and changes in lipid parameters, which may affect adherence. Patient education regarding lifestyle modifications, adequate calcium and vitamin D intake, weight-bearing exercise, and strategies to manage treatment-related adverse effects may improve long-term treatment persistence.

Pharmacists should evaluate the patient's medication history to prevent any drug-drug and drug-supplement interactions. Additionally, they should assess adherence to aromatase inhibitors and evaluate causes of non-adherence. Measures should be taken to provide possible solutions to reduce barriers to compliance, such as adverse drug effects and financial cost issues.[46]

Nurses should provide patient counseling on the medication, answer patient questions, and serve as a point of contact for patients and other interprofessional team members. Additionally, they play a key role in reinforcing adherence, monitoring adverse effects, and facilitating communication among members of the healthcare team. Case management should include counseling regarding improving bone health and monitoring bone mineral density, with consideration of bone-protective therapies when clinically indicated.

Using these interprofessional strategies alongside aromatase inhibitor therapy may improve adherence, enhance patient safety, strengthen care coordination, and optimize therapeutic outcomes while reducing adverse events.

References

[1]

Arora A, Potter JF. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. Journal of the American Geriatrics Society. 2004 Apr:52(4):611-6 [PubMed PMID: 15066080]

[2]

Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocrine reviews. 2005 May:26(3):331-45 [PubMed PMID: 15814851]

Level 3 (low-level) evidence

[3]

Tominaga T, Adachi I, Sasaki Y, Tabei T, Ikeda T, Takatsuka Y, Toi M, Suwa T, Ohashi Y. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Jan:14(1):62-70 [PubMed PMID: 12488294]

Level 1 (high-level) evidence

[4]

Kleeberg UR, Dowsett M, Carrion RP, Dodwell DJ, Vorobiof DA, Aparicio LA, Robertson JF. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer. Oncology. 1997:54 Suppl 2():19-22 [PubMed PMID: 9394856]

Level 1 (high-level) evidence

[5]

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Jul 20:32(21):2255-69. doi: 10.1200/JCO.2013.54.2258. Epub 2014 May 27 [PubMed PMID: 24868023]

Level 1 (high-level) evidence

[6]

Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Oct 20:26(30):4883-90. doi: 10.1200/JCO.2007.14.4659. Epub 2008 Sep 15 [PubMed PMID: 18794551]

Level 1 (high-level) evidence

[7]

Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs. 2004:64(11):1213-30 [PubMed PMID: 15161328]

[8]

Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert opinion on investigational drugs. 2003 Mar:12(3):337-51 [PubMed PMID: 12605559]

Level 3 (low-level) evidence

[9]

Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors: potential reproductive implications. Journal of minimally invasive gynecology. 2009 Sep-Oct:16(5):533-9. doi: 10.1016/j.jmig.2009.05.009. Epub 2009 Jul 15 [PubMed PMID: 19608462]

[10]

Santen RJ. Inhibition of aromatase: insights from recent studies. Steroids. 2003 Sep:68(7-8):559-67 [PubMed PMID: 12957661]

Level 3 (low-level) evidence

[11]

Zagouri F, Sergentanis TN, Azim HA Jr, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Aromatase inhibitors in male breast cancer: a pooled analysis. Breast cancer research and treatment. 2015 May:151(1):141-7. doi: 10.1007/s10549-015-3356-9. Epub 2015 Apr 8 [PubMed PMID: 25850534]

[12]

Tan RB, Guay AT, Hellstrom WJ. Clinical Use of Aromatase Inhibitors in Adult Males. Sexual medicine reviews. 2014 Apr:2(2):79-90. doi: 10.1002/smrj.23. Epub 2015 Oct 19 [PubMed PMID: 27784593]

[13]

Hero M. Aromatase Inhibitors in the Treatment of Short Stature. Endocrine development. 2016:30():130-40. doi: 10.1159/000439338. Epub 2015 Dec 10 [PubMed PMID: 26684331]

[14]

del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV. Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecologic oncology. 2003 Dec:91(3):596-602 [PubMed PMID: 14675683]

[15]

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, TEXT and SOFT Investigators, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England journal of medicine. 2014 Jul 10:371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1 [PubMed PMID: 24881463]

[16]

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet. Oncology. 2022 Mar:23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3 [PubMed PMID: 35123662]

Level 1 (high-level) evidence

[17]

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Nov 20:37(33):3152-3165. doi: 10.1200/JCO.19.01472. Epub 2019 Sep 3 [PubMed PMID: 31479306]

Level 1 (high-level) evidence

[18]

Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, Lønning PE, Llombart A, Maass N, Maudelonde T, Sasano H, Goss PE. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The oncologist. 2008 Aug:13(8):829-37. doi: 10.1634/theoncologist.2008-0055. Epub 2008 Aug 11 [PubMed PMID: 18695261]

[19]

Blakemore J, Naftolin F. Aromatase: Contributions to Physiology and Disease in Women and Men. Physiology (Bethesda, Md.). 2016 Jul:31(4):258-69. doi: 10.1152/physiol.00054.2015. Epub [PubMed PMID: 27252161]

[20]

Nabholtz JM. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Therapeutics and clinical risk management. 2008 Feb:4(1):189-204 [PubMed PMID: 18728707]

[21]

Forbes JF. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Seminars in oncology. 2006 Apr:33(2 Suppl 7):S2-7 [PubMed PMID: 16730270]

Level 1 (high-level) evidence

[22]

Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Przeglad menopauzalny = Menopause review. 2016 Mar:15(1):43-7. doi: 10.5114/pm.2016.58773. Epub 2016 Mar 29 [PubMed PMID: 27095958]

[23]

Abu Hashim H. Potential role of aromatase inhibitors in the treatment of endometriosis. International journal of women's health. 2014:6():671-80. doi: 10.2147/IJWH.S34684. Epub 2014 Jul 21 [PubMed PMID: 25092998]

[24]

de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reproductive biology and endocrinology : RB&E. 2011 Jun 21:9():93. doi: 10.1186/1477-7827-9-93. Epub 2011 Jun 21 [PubMed PMID: 21693046]

[25]

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Feb 10:37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19 [PubMed PMID: 30452337]

Level 1 (high-level) evidence

[26]

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet. Oncology. 2010 Dec:11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17 [PubMed PMID: 21087898]

Level 1 (high-level) evidence

[27]

Sini V, Botticelli A, Lunardi G, Gori S, Marchetti P. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. Pharmacogenomics. 2017 Jun:18(8):821-830. doi: 10.2217/pgs-2017-0006. Epub 2017 Jun 8 [PubMed PMID: 28592202]

[28]

Krásenská M. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2016 Fall:29 Suppl 3():S39-49. doi: 10.14735/amko20163S39. Epub [PubMed PMID: 28118723]

[29]

Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L, Gori S. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. Clinical breast cancer. 2017 Feb:17(1):11-17. doi: 10.1016/j.clbc.2016.07.003. Epub 2016 Jul 25 [PubMed PMID: 27561703]

[30]

Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K. Skeletal complications of breast cancer therapies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Oct 15:12(20 Pt 2):6309s-6314s [PubMed PMID: 17062720]

[31]

Erbağ G, Uygun K, Binnetoğlu E, Korkmaz AN, Aşık M, Şen H, Güneş F, Eroğlu M, Gökmen F, Temiz S. Aromatase inhibitor treatment for breast cancer: short-term effect on bone health. Contemporary oncology (Poznan, Poland). 2015:19(5):374-7. doi: 10.5114/wo.2014.45305. Epub 2015 Aug 7 [PubMed PMID: 26793021]

[32]

Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast (Edinburgh, Scotland). 2007 Jun:16(3):223-34 [PubMed PMID: 17368903]

[33]

Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Apr 1:33(10):1104-11. doi: 10.1200/JCO.2014.57.1547. Epub 2014 Dec 1 [PubMed PMID: 25452437]

Level 1 (high-level) evidence

[34]

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1:36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 Nov 14 [PubMed PMID: 29136387]

Level 1 (high-level) evidence

[35]

Hershman DL, Unger JM, Greenlee H, Capodice J, Lew DL, Darke A, Minasian LM, Fisch MJ, Henry NL, Crew KD. Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial. JAMA network open. 2022 Nov 1:5(11):e2241720. doi: 10.1001/jamanetworkopen.2022.41720. Epub 2022 Nov 1 [PubMed PMID: 36367721]

Level 1 (high-level) evidence

[36]

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA. 2018 Jul 10:320(2):167-176. doi: 10.1001/jama.2018.8907. Epub [PubMed PMID: 29998338]

Level 1 (high-level) evidence

[37]

Meyer H, Koppold DA, Shaker O, Eden L, Schiffmann L, Konigorski S, Cramer H, Choi KA, Einsele H, Winkler M, Löffler C. Therapeutic Fasting as a Novel Approach to Mitigate Musculoskeletal Symptoms in Breast Cancer Patients undergoing Aromatase Inhibitor Therapy: A Feasibility Study Protocol. Integrative cancer therapies. 2026 Jan-Dec:25():15347354261426272. doi: 10.1177/15347354261426272. Epub 2026 Mar 10 [PubMed PMID: 41805449]

Level 2 (mid-level) evidence

[38]

Duraes M, Garbay M, Ferrer C, Duflos C, Rathat G. Effect of whole-body cryotherapy versus placebo cryotherapy on joint pain induced by aromatase inhibitors in women with early stage breast cancer: a randomised clinical trial. BMJ open. 2023 Dec 9:13(12):e071756. doi: 10.1136/bmjopen-2023-071756. Epub 2023 Dec 9 [PubMed PMID: 38070928]

Level 1 (high-level) evidence

[39]

Skafida E, Andrikopoulou A, Terpos E, Markellos C, Moustafa S, Pectasides D, Dimopoulos MA, Zagouri F, Vassilopoulos D. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting. The breast journal. 2023:2023():3614296. doi: 10.1155/2023/3614296. Epub 2023 May 31 [PubMed PMID: 37293258]

[40]

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Mar 20:30(9):936-42. doi: 10.1200/JCO.2011.38.0261. Epub 2012 Feb 13 [PubMed PMID: 22331951]

[41]

Tiboni GM, Ponzano A. Fetal safety profile of aromatase inhibitors: Animal data. Reproductive toxicology (Elmsford, N.Y.). 2016 Dec:66():84-92. doi: 10.1016/j.reprotox.2016.09.016. Epub 2016 Sep 30 [PubMed PMID: 27697604]

Level 3 (low-level) evidence

[42]

Van Poznak C, Makris A, Clack G, Barlow DH, Eastell R. Lipid profiles within the SABRE trial of anastrozole with and without risedronate. Breast cancer research and treatment. 2012 Aug:134(3):1141-7. doi: 10.1007/s10549-012-2147-9. Epub 2012 Jul 5 [PubMed PMID: 22763465]

Level 1 (high-level) evidence

[43]

Gonnelli S, Petrioli R. Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. Clinical interventions in aging. 2008:3(4):647-57 [PubMed PMID: 19281057]

[44]

Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. European journal of cancer (Oxford, England : 1990). 1996 Mar:32A(3):404-12 [PubMed PMID: 8814682]

Level 1 (high-level) evidence

[45]

Fabbri MA, Fulvi A, Vergati M, D'Auria G, Vici P, Filomeno L, Arcuri T, Palazzo A, Nelli F, Fiore C, Portarena I, Falbo PT, Rossi R, Alesini D, Sini V, Pace R, Frittelli P, Corsi DC, Palombi L, Pisegna S, Botticelli A, Scagnoli S, Pistillucci G, Giordani E, La Cesa A. Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study. The breast journal. 2025:2025():8976679. doi: 10.1155/tbj/8976679. Epub 2025 Dec 19 [PubMed PMID: 41438121]

[46]

Wang L, Zhang Y, Wei Q, Liang X, Zhou J, Ma A, Wang L. The effect of pharmacist intervention on medication adherence measured with proportion of days covered: a systematic review and meta-analysis. International journal of clinical pharmacy. 2025 Dec:47(6):1590-1608. doi: 10.1007/s11096-025-01974-4. Epub 2025 Aug 7 [PubMed PMID: 40775483]

Level 1 (high-level) evidence